Health-related quality of life burden in scleroderma patients treated with two different intravenous iloprost regimens
Systemic sclerosis (SSc)-related Raynaud’s phenomenon (RP) and digital ulcers (DU) can impair health-related quality of life (HRQoL). The aim of our study was to estimate HRQoL in SSc patients treated with two different intravenous (IV) iloprost (ILO) regimens and in patients not treated with IV ILO...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2019-07-01
|
| Series: | Reumatismo |
| Subjects: | |
| Online Access: | https://www.reumatismo.org/index.php/reuma/article/view/1190 |
| _version_ | 1818038254063058944 |
|---|---|
| author | T. Schioppo L. Scalone P. Cozzolino L. Mantovani G. Cesana O. De Lucia A. Murgo F. Ingegnoli |
| author_facet | T. Schioppo L. Scalone P. Cozzolino L. Mantovani G. Cesana O. De Lucia A. Murgo F. Ingegnoli |
| author_sort | T. Schioppo |
| collection | DOAJ |
| description | Systemic sclerosis (SSc)-related Raynaud’s phenomenon (RP) and digital ulcers (DU) can impair health-related quality of life (HRQoL). The aim of our study was to estimate HRQoL in SSc patients treated with two different intravenous (IV) iloprost (ILO) regimens and in patients not treated with IV ILO. 96 consecutive SSc patients were enrolled in a pragmatic, prospective and non-randomized study, and divided into 3 groups: not requiring therapy with IV ILO (N=52), IV ILO once monthly (N=24) or IV ILO for 5 consecutive days every 3 months (N=20). Patients were followed up for three months. We assessed HRQoL using the generic preference-based questionnaire EQ-5D-5L. We conducted multiple regression analyses to estimate, in each treatment group, the mean general health (GH) and the mean utility index of the EQ-5D-5L, adjusting for possible confounders. The mean adjusted utility index and GH score, after three months’ follow-up, were not different in the three groups: IV ILO was able to make patients requiring IV ILO similar to those not requiring it. Moreover, there was no difference in this model between the two ILO regimens (1 day monthly vs 5 consecutive days every 3 months). The two different IV ILO regimens (the most appropriate regimen was decided according to patients’ characteristics and needs) were able to stabilize HRQoL in RP secondary to SSc non-adequately controlled by oral therapy. |
| first_indexed | 2024-12-10T07:39:49Z |
| format | Article |
| id | doaj.art-4462cac0caab4574a2d955b5f0e69e53 |
| institution | Directory Open Access Journal |
| issn | 0048-7449 2240-2683 |
| language | English |
| last_indexed | 2024-12-10T07:39:49Z |
| publishDate | 2019-07-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Reumatismo |
| spelling | doaj.art-4462cac0caab4574a2d955b5f0e69e532022-12-22T01:57:19ZengPAGEPress PublicationsReumatismo0048-74492240-26832019-07-0171210.4081/reumatismo.2019.1190Health-related quality of life burden in scleroderma patients treated with two different intravenous iloprost regimensT. Schioppo0L. Scalone1P. Cozzolino2L. Mantovani3G. Cesana4O. De Lucia5A. Murgo6F. Ingegnoli7Division of Clinical Rheumatology, ASST Pini-CTO, Milano, Italy; Department of Clinical Sciences & Community Health, Università degli Studi di MilanoCentro di Studio e Ricerca sulla Sanità Pubblica (CESP), Università degli Studi di Milano Bicocca, Monza, Italy; Fondazione CHARTA, MilanoCentro di Studio e Ricerca sulla Sanità Pubblica (CESP), Università degli Studi di Milano Bicocca, MonzaCentro di Studio e Ricerca sulla Sanità Pubblica (CESP), Università degli Studi di Milano Bicocca, Monza, Italy; Fondazione CHARTA, MilanoCentro di Studio e Ricerca sulla Sanità Pubblica (CESP), Università degli Studi di Milano Bicocca, MonzaDivision of Clinical Rheumatology, ASST Pini-CTO, MilanoDivision of Clinical Rheumatology, ASST Pini-CTO, MilanoDivision of Clinical Rheumatology, ASST Pini-CTO, Milano, Italy; Department of Clinical Sciences & Community Health, Università degli Studi di MilanoSystemic sclerosis (SSc)-related Raynaud’s phenomenon (RP) and digital ulcers (DU) can impair health-related quality of life (HRQoL). The aim of our study was to estimate HRQoL in SSc patients treated with two different intravenous (IV) iloprost (ILO) regimens and in patients not treated with IV ILO. 96 consecutive SSc patients were enrolled in a pragmatic, prospective and non-randomized study, and divided into 3 groups: not requiring therapy with IV ILO (N=52), IV ILO once monthly (N=24) or IV ILO for 5 consecutive days every 3 months (N=20). Patients were followed up for three months. We assessed HRQoL using the generic preference-based questionnaire EQ-5D-5L. We conducted multiple regression analyses to estimate, in each treatment group, the mean general health (GH) and the mean utility index of the EQ-5D-5L, adjusting for possible confounders. The mean adjusted utility index and GH score, after three months’ follow-up, were not different in the three groups: IV ILO was able to make patients requiring IV ILO similar to those not requiring it. Moreover, there was no difference in this model between the two ILO regimens (1 day monthly vs 5 consecutive days every 3 months). The two different IV ILO regimens (the most appropriate regimen was decided according to patients’ characteristics and needs) were able to stabilize HRQoL in RP secondary to SSc non-adequately controlled by oral therapy.https://www.reumatismo.org/index.php/reuma/article/view/1190Iloprostprostacyclinsystemic sclerosishealth related quality of lifeEQ-5D-5L |
| spellingShingle | T. Schioppo L. Scalone P. Cozzolino L. Mantovani G. Cesana O. De Lucia A. Murgo F. Ingegnoli Health-related quality of life burden in scleroderma patients treated with two different intravenous iloprost regimens Reumatismo Iloprost prostacyclin systemic sclerosis health related quality of life EQ-5D-5L |
| title | Health-related quality of life burden in scleroderma patients treated with two different intravenous iloprost regimens |
| title_full | Health-related quality of life burden in scleroderma patients treated with two different intravenous iloprost regimens |
| title_fullStr | Health-related quality of life burden in scleroderma patients treated with two different intravenous iloprost regimens |
| title_full_unstemmed | Health-related quality of life burden in scleroderma patients treated with two different intravenous iloprost regimens |
| title_short | Health-related quality of life burden in scleroderma patients treated with two different intravenous iloprost regimens |
| title_sort | health related quality of life burden in scleroderma patients treated with two different intravenous iloprost regimens |
| topic | Iloprost prostacyclin systemic sclerosis health related quality of life EQ-5D-5L |
| url | https://www.reumatismo.org/index.php/reuma/article/view/1190 |
| work_keys_str_mv | AT tschioppo healthrelatedqualityoflifeburdeninsclerodermapatientstreatedwithtwodifferentintravenousiloprostregimens AT lscalone healthrelatedqualityoflifeburdeninsclerodermapatientstreatedwithtwodifferentintravenousiloprostregimens AT pcozzolino healthrelatedqualityoflifeburdeninsclerodermapatientstreatedwithtwodifferentintravenousiloprostregimens AT lmantovani healthrelatedqualityoflifeburdeninsclerodermapatientstreatedwithtwodifferentintravenousiloprostregimens AT gcesana healthrelatedqualityoflifeburdeninsclerodermapatientstreatedwithtwodifferentintravenousiloprostregimens AT odelucia healthrelatedqualityoflifeburdeninsclerodermapatientstreatedwithtwodifferentintravenousiloprostregimens AT amurgo healthrelatedqualityoflifeburdeninsclerodermapatientstreatedwithtwodifferentintravenousiloprostregimens AT fingegnoli healthrelatedqualityoflifeburdeninsclerodermapatientstreatedwithtwodifferentintravenousiloprostregimens |